Quanterix Corporation (NASDAQ:QTRX) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Quanterix Corporation (NASDAQ:QTRX) has received an average rating of "Hold" from five research firms, with four hold recommendations and one buy recommendation, reflecting cautious sentiment among analysts.
• Recent insider activity includes two directors purchasing a significant number of shares, indicating confidence in the company's potential, with a total of 463,113 shares worth $2,625,444 bought in the last quarter.
• The company's stock price has seen volatility, recently trading at $4.49, down 1.3%, and reported earnings that missed consensus estimates with a negative net margin of 56.04%.

Shares of Quanterix Corporation (NASDAQ:QTRX - Get Free Report) have earned an average rating of "Hold" from the five research firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $11.75.

QTRX has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Canaccord Genuity Group reissued a "hold" rating and issued a $5.00 price target (down from $12.00) on shares of Quanterix in a research note on Monday, August 11th.

Insiders Place Their Bets

In related news, Director William P. Donnelly purchased 93,113 shares of Quanterix stock in a transaction on Friday, June 6th. The stock was acquired at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the completion of the acquisition, the director owned 139,094 shares of the company's stock, valued at $756,671.36. This trade represents a 202.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David R. Walt purchased 131,869 shares of the firm's stock in a transaction on Friday, June 6th. The stock was bought at an average cost of $5.43 per share, with a total value of $716,048.67. Following the completion of the purchase, the director owned 1,628,802 shares of the company's stock, valued at approximately $8,844,394.86. This represents a 8.81% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 463,113 shares of company stock worth $2,625,444 in the last quarter. 6.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in QTRX. Tower Research Capital LLC TRC grew its stake in Quanterix by 219.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock valued at $61,000 after acquiring an additional 3,915 shares during the period. State of Wyoming acquired a new stake in Quanterix in the 1st quarter valued at $47,000. ProShare Advisors LLC acquired a new stake in Quanterix in the 4th quarter valued at $108,000. Cetera Investment Advisers bought a new stake in Quanterix during the 4th quarter valued at $108,000. Finally, Quantbot Technologies LP raised its holdings in Quanterix by 245.9% during the first quarter. Quantbot Technologies LP now owns 11,272 shares of the company's stock worth $73,000 after buying an additional 8,013 shares during the last quarter. 86.48% of the stock is owned by institutional investors and hedge funds.

Quanterix Stock Down 1.3%

QTRX opened at $4.49 on Wednesday. Quanterix has a twelve month low of $4.05 and a twelve month high of $15.85. The company has a fifty day moving average of $5.56 and a 200-day moving average of $5.92. The stock has a market cap of $208.65 million, a PE ratio of -2.47 and a beta of 1.03.

Quanterix (NASDAQ:QTRX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06). The firm had revenue of $24.48 million during the quarter, compared to analyst estimates of $29.73 million. Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. Quanterix has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Quanterix will post -0.98 EPS for the current fiscal year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.